eyeforpharma is now Reuters Events - LEARN MORE
Pharma gets Serious about Drug Adherence
How is pharma tackling adherence? S3 Group, specialists in connected health, and eyeforpharma developed a survey to investigate.
There were over 200 respondents from eyeforpharma’s database of pharma organizations, covering the following market regions: US/North America (29.3%); Global (16.1%); Europe (36.2%); Asia Pacific (9.8%); Middle East/Africa (4%); and, South America (4.6%). S3 are crunching the data, which will be presented as a full report. In the meantime, here is a flavor of what we have found.
The number of active adherence-related projects currently underway within the pharma industry demonstrates that the industry is taking drug adherence seriously. Indeed, 2 out of 3 respondents had attempted, were planning, or were currently implementing or piloting initiatives. Respondents reported the use of online medication or condition management services, online patient education, and online adherence coaching, SMS reminders, behavior change initiatives and connected medication devices to help address the adherence issue.
The data demonstrates that pharma companies are motivated both financially and clinically to solve the problem of non-adherence; 97% of respondents believe that lack of adherence has a significant impact on patient outcomes and 84% indicate that lack of adherence has a significant impact on revenues.
Please click for a larger version of the infographic
While perfect adherence is clearly not possible, 87% of respondents believe that medication adherence can be improved by 10% or more. If this figure is achieved then the market opportunity open to pharma, in terms of medication sales, is equivalent to a market the size of Japan.
There appears to be a growing consensus that technology now exists to help address the difficult issue of patient adherence. Indeed, 72% agreed or strongly agreed with the statement, “If pharma can engage patients using digital and mobile technologies then they can boost adherence rates.”
With increased capability and motivation to tackle issues surrounding medical adherence, comes increased investment – 2 out of 3 respondents predict an increased growth in investment over the next 3 years, with 20% predicting that this growth will exceed 50% on current levels.
This is just a taster of what our survey has revealed. The full report will be available in due course.
S3 Group are specialists in the provision of connected health solutions to pharma and healthcare organizations. For more information, visit www.s3group.com/connected-health/
Since you're here...
... and value our content, you should sign-up to our newsletter. Sign up here